NVAX - Novavax, Inc.
NEXT EARNINGS:
Feb 26, 2026
(in 1 day)
EPS Est: $-0.66
|
Rev Est: $90.3M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$14.50
DETAILS
HIGH:
$18.00
LOW:
$11.00
MEDIAN:
$14.50
CONSENSUS:
$14.50
UPSIDE:
53.28%
Market Cap:
1.54B
Volume:
2,915,681
Avg Volume:
4,319,345
52 Week Range:
5.01-10.64
Sector:
Healthcare
Industry:
Biotechnology
Beta:
2.58
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
952
IPO Date:
1995-12-05
EPS (TTM):
-1.23
P/E Ratio:
-6.53
Revenue (TTM):
682.16M
Total Assets:
1.56B
Total Debt:
230.42M
Cash & Equiv:
530.23M
Rev Growth (5Y):
105.3%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-38.6%
Debt/Equity:
-0.37
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-06 | $-0.62 | $-1.08 | +42.6% | $70.4M | $90.3M | -22.0% |
| 2025-08-06 | $0.62 | $-0.07 | +985.7% | $239.2M | $55.6M | +330.1% |
| 2025-05-08 | $2.93 | $0.71 | +312.7% | $666.7M | $343.9M | +93.9% |
| 2025-02-27 | $-0.51 | $-0.75 | +32.0% | $88.3M | $84.4M | +4.7% |
| 2024-11-12 | $-0.76 | $-0.87 | +12.6% | $84.5M | $90.9M | -7.1% |
| 2024-08-08 | $0.99 | $1.64 | -39.6% | $415.5M | $458.6M | -9.4% |
| 2024-05-10 | $-1.05 | $-1.04 | -1.0% | $93.9M | $101.2M | -7.2% |
| 2024-02-28 | $-1.44 | $-0.49 | -193.9% | $291.3M | $322.0M | -9.5% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 682.16M | 556.38M | 1.60B | 197.58M | 22.39M | 18.66M | 34.29M | 31.18M | 15.35M | 36.25M | 30.66M | 20.91M |
| Net Income | (187.50M) | (545.06M) | (657.94M) | (1.74B) | (418.26M) | (130.10M) | (184.75M) | (183.77M) | (279.97M) | (156.94M) | (82.95M) | (51.98M) |
| EPS | -1.23 | -5.41 | -8.42 | -23.44 | -7.43 | -5.40 | -9.99 | -12.56 | -20.68 | -11.97 | -7.35 | -6.13 |
| Total Assets | 1.56B | 1.80B | 2.26B | 2.58B | 1.58B | 172.96M | 207.98M | 302.49M | 394.30M | 386.04M | 276.00M | 235.94M |
| Total Debt | 230.42M | 229.08M | 549.78M | 453.99M | 467.98M | 321.87M | 319.19M | 317.76M | 316.34M | 395,000 | 998,000 | 2.18M |
| Cash & Equivalents | 530.23M | 568.50M | 1.34B | 1.52B | 553.40M | 78.82M | 70.15M | 106.31M | 144.35M | 93.11M | 32.34M | 119.47M |
| Operating Cash Flow | (87.26M) | (713.97M) | (415.94M) | 322.95M | (42.54M) | (136.62M) | (184.82M) | (138.70M) | (255.47M) | (126.09M) | (67.01M) | (45.36M) |
| Free Cash Flow | (100.32M) | (772.77M) | (508.92M) | 265.46M | (97.16M) | (138.48M) | (186.20M) | (142.88M) | (273.68M) | (144.38M) | (74.28M) | (51.14M) |
| FCF per Share | -0.66 | -7.67 | -6.51 | 3.57 | -1.69 | -5.75 | -10.07 | -9.76 | -20.21 | -11.01 | -6.58 | -6.03 |
| Book Value | (623.84M) | (716.93M) | (634.08M) | (351.67M) | 627.21M | (186.02M) | (167.94M) | (101.73M) | (5.55M) | 292.67M | 229.62M | 203.23M |
| Cash & ST Investments | 923.12M | 568.50M | 1.34B | 1.52B | 711.05M | 78.82M | 70.15M | 106.31M | 144.35M | 230.66M | 168.06M | 133.07M |
| ROC Equity | N/A | N/A | N/A | N/A | -0.67 | N/A | N/A | N/A | N/A | -0.54 | -0.36 | -0.26 |